EAST HANOVER, N.J. — December 12, 2025 — Novartis, a global innovative medicines company, has officially broken ground on a more than 700,000-square-foot flagship manufacturing hub in North Carolina, marking a major milestone in its long-term strategy to ensure end-to-end domestic manufacturing of key medicines for U.S. patients. The groundbreaking, attended by senior company leadership, U.S. FDA Commissioner Marty Makary, and North Carolina Governor Josh Stein, reflects Novartis’ expanding commitment to resilient, large-scale pharmaceutical manufacturing in the United States

Science Significance

From a scientific perspective, the new manufacturing hub strengthens Novartis’ ability to deliver high-quality, complex medicines at scale across its core therapeutic areas, including oncology, neuroscience, immunology, and renal disease. The integrated facilities in Morrisville and Durham, combined with expansion of an existing Durham site, will support advanced manufacturing technologies, process innovation, and lifecycle management. By consolidating end-to-end capabilities within the U.S., Novartis enhances process control, reproducibility, and supply reliability, which are essential to maintaining scientific rigor from development through commercial production.

Regulatory Significance

The project carries substantial regulatory importance, reinforcing cGMP-aligned domestic manufacturing capacity at a time of heightened regulatory focus on supply chain resilience and national drug security. The presence of FDA leadership at the groundbreaking highlights regulatory support for investments that reduce dependency on overseas manufacturing. By producing all key medicines for U.S. patients domestically, Novartis strengthens its ability to meet FDA quality expectations, inspection readiness, and compliance oversight, while reducing risks associated with cross-border supply disruptions.

Business Significance

From a business standpoint, the North Carolina hub represents a cornerstone of Novartis’ $23 billion investment in U.S.-based infrastructure over the next five years. The project is expected to create 700 new direct jobs by 2030 and support more than 3,000 indirect jobs across the U.S. supply chain, reinforcing the company’s economic footprint. The investment aligns with Novartis’ broader U.S. expansion strategy, which in 2025 also included multiple FDA approvals, expanded R&D capabilities, and new radioligand therapy manufacturing sites, positioning the company for sustainable growth and operational efficiency.

Patients’ Significance

For patients, the manufacturing hub directly supports timely access to essential medicines. Domestic, end-to-end production reduces vulnerability to global disruptions and enables faster response to demand fluctuations, particularly for therapies addressing serious and chronic diseases. By strengthening its U.S. manufacturing base, Novartis reinforces its commitment to ensuring that patients receive consistent, high-quality treatments without interruption, supporting both current therapies and future innovations reaching the market.

Policy Significance

At a policy level, the groundbreaking underscores alignment between industry investment and U.S. manufacturing and healthcare security priorities. Federal and state leaders emphasized the role of advanced pharmaceutical manufacturing in supporting national resilience, public health preparedness, and economic development. The project serves as a case study for how clear regulatory frameworks and public-private alignment can encourage large-scale investments that strengthen domestic life sciences infrastructure while safeguarding patient access.

Novartis’ flagship manufacturing hub in North Carolina represents a decisive step toward integrated, compliant, and resilient pharmaceutical manufacturing in the United States. By combining scientific excellence, regulatory alignment, and long-term business investment, the company is positioning itself to deliver innovative medicines at scale while supporting patients, regulators, and the broader healthcare system. For the cGxP.wire audience, the project highlights how strategic manufacturing investments are becoming central to modern pharmaceutical science, compliance, and patient impact.

Source: Novartis press release